Cover Image
市場調查報告書

骨髓纖維化:開發平台評估

Myelofibrosis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 219837
出版日期 內容資訊 英文 189 Pages
訂單完成後即時交付
價格
Back to Top
骨髓纖維化:開發平台評估 Myelofibrosis - Pipeline Review, H2 2015
出版日期: 2015年09月30日 內容資訊: 英文 189 Pages
簡介

所謂骨髓纖維化(MF),屬於稱為「骨髓增生性腫瘤(MPN)」的疾病群,正常的血液細胞的生產受損的嚴重骨髓障礙。有腹痛、疲勞感、發熱、骨頭及肌肉的疼痛、搔癢、呼吸急促等症狀,有年齡、化學物質的暴露、放射線的暴露、血液疾病等原因。治療方法有化療、幹細胞移植、放射治療等。

本報告提供全球骨髓纖維化治療藥的開發平台相關研究、目前開發平台狀況和最新趨勢、藥物簡介、主要企業及開發中的產品檢討等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

骨髓纖維化概要

治療藥的開發

  • 骨髓纖維化的開發中產品:概要
  • 骨髓纖維化的開發中產品:比較分析

骨髓纖維化:開發中治療藥:各企業

骨髓纖維化:開發中治療藥:各大學、研究機關

骨髓纖維化:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

骨髓纖維化:開發中的產品:各企業

骨髓纖維化:開發中的產品:各大學、研究機關

骨髓纖維化:治療藥開發企業

  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Novartis AG
  • Cell Therapeutics, Inc.
  • Celgene Corporation
  • Incyte Corporation
  • Geron Corporation
  • MEI Pharma, Inc.
  • Threshold Pharmaceuticals, Inc.
  • Acceleron Pharma, Inc.
  • Promedior, Inc.

骨髓纖維化:治療藥的評估

  • 單劑治療藥
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • pacritinib
  • momelotinib
  • ruxolitinib phosphate
  • pomalidomide
  • SAR-2305
  • sotatercept
  • imetelstat sodium
  • panobinostat
  • pracinostat
  • PRM-151
  • LCL-161
  • luminespib
  • simtuzumab
  • gandotinib
  • INCB-39110
  • AZD-1480
  • erismodegib
  • BMS-911543
  • NS-018
  • TH-302
  • buparlisib hydrochloride
  • 癌症及血液疾病的JAK抑制小分子
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

中止的產品

產品開發里程碑

  • 關注的新聞、新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6980IDB

Summary

Global Markets Direct's, 'Myelofibrosis - Pipeline Review, H2 2015', provides an overview of the Myelofibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myelofibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Myelofibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Myelofibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Myelofibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myelofibrosis Overview
  • Therapeutics Development
    • Pipeline Products for Myelofibrosis - Overview
    • Pipeline Products for Myelofibrosis - Comparative Analysis
  • Myelofibrosis - Therapeutics under Development by Companies
  • Myelofibrosis - Therapeutics under Investigation by Universities/Institutes
  • Myelofibrosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Myelofibrosis - Products under Development by Companies
  • Myelofibrosis - Products under Investigation by Universities/Institutes
  • Myelofibrosis - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • CTI BioPharma Corp.
    • Galena Biopharma, Inc.
    • Gilead Sciences, Inc.
    • Incyte Corporation
    • Italfarmaco S.p.A.
    • Johnson & Johnson
    • JW Pharmaceutical Corporation
    • KaloBios Pharmaceuticals, Inc.
    • Nippon Shinyaku Co., Ltd.
    • Novartis AG
    • Onconova Therapeutics, Inc.
    • Pfizer Inc.
    • PharmaEssentia Corporation
    • Promedior, Inc.
    • Stemline Therapeutics, Inc.
    • Threshold Pharmaceuticals, Inc.
  • Myelofibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • anagrelide hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMS-911543 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buparlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CWP-291 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • erismodegib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • evofosfamide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • givinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • glasdegib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Hu8F4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • idelalisib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • imetelstat sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-39110 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KB-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LCL-161 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • momelotinib dihydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NS-018 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pacritinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pixantrone dimaleate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pomalidomide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRM-151 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rigosertib sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ropeginterferon ALFA-2B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • simtuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sotatercept - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Myelofibrosis - Recent Pipeline Updates
  • Myelofibrosis - Dormant Projects
  • Myelofibrosis - Discontinued Products
  • Myelofibrosis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 16, 2015: Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis
      • Jun 12, 2015: Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis
      • Jun 12, 2015: Promedior Presents Additional Positive Phase 2 Data for PRM-151 in Myelofibrosis at EHA Annual Meeting
      • Jun 10, 2015: CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA
      • Jun 04, 2015: Promedior Announces Presentation of Additional Positive Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming Congress of the European Hematology Association
      • May 30, 2015: Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
      • May 14, 2015: Baxter BioScience to Present New Data at ASCO On Pacritinib from Expanding Oncology Pipeline Designed to Address Unmet Needs in Challenging Cancers
      • Apr 27, 2015: Geron to Present at the Bank of America Merrill Lynch Healthcare Conference
      • Apr 22, 2015: CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO
      • Mar 16, 2015: CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Myelofibrosis, H2 2015
  • Number of Products under Development for Myelofibrosis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Myelofibrosis - Pipeline by Acceleron Pharma, Inc., H2 2015
  • Myelofibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Myelofibrosis - Pipeline by Celgene Corporation, H2 2015
  • Myelofibrosis - Pipeline by CTI BioPharma Corp., H2 2015
  • Myelofibrosis - Pipeline by Galena Biopharma, Inc., H2 2015
  • Myelofibrosis - Pipeline by Gilead Sciences, Inc., H2 2015
  • Myelofibrosis - Pipeline by Incyte Corporation, H2 2015
  • Myelofibrosis - Pipeline by Italfarmaco S.p.A., H2 2015
  • Myelofibrosis - Pipeline by Johnson & Johnson, H2 2015
  • Myelofibrosis - Pipeline by JW Pharmaceutical Corporation, H2 2015
  • Myelofibrosis - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015
  • Myelofibrosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
  • Myelofibrosis - Pipeline by Novartis AG, H2 2015
  • Myelofibrosis - Pipeline by Onconova Therapeutics, Inc., H2 2015
  • Myelofibrosis - Pipeline by Pfizer Inc., H2 2015
  • Myelofibrosis - Pipeline by PharmaEssentia Corporation, H2 2015
  • Myelofibrosis - Pipeline by Promedior, Inc., H2 2015
  • Myelofibrosis - Pipeline by Stemline Therapeutics, Inc., H2 2015
  • Myelofibrosis - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Myelofibrosis Therapeutics - Recent Pipeline Updates, H2 2015
  • Myelofibrosis - Dormant Projects, H2 2015
  • Myelofibrosis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Myelofibrosis, H2 2015
  • Number of Products under Development for Myelofibrosis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top